BD & BioMedomics Announce Launch Of Rapid Serology Test To Detect Exposure To COVID-19

BD (Becton, Dickinson and Company), a global medical technology company, and BioMedomics, a privately held, North Carolina-based clinical diagnostics company, announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in as little as 15 minutes. The new test, developed and manufactured by BioMedomics, will be available through BD and distributed exclusively by Henry Schein, Inc. to health care provider organizations throughout the United States.

The test does not require special equipment and may be used in a laboratory or at the point of . . .